within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED01_Crizotinib;

model Crizotinib
  extends Pharmacolibrary.Drugs.ATC.L.L01ED01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01ED01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Crizotinib is an orally administered small-molecule inhibitor of ALK (anaplastic lymphoma kinase), ROS1, and MET tyrosine kinases used for the treatment of ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). It is approved for use in adults with advanced or metastatic NSCLC.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients, oral administration, typical dose 250 mg twice daily, analyzed as a two-compartment model with first-order absorption.</p><h4>References</h4><ol><li><p>Shaw, AT, et al., &amp; Iafrate, AJ (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>The New England journal of medicine</i> 371(21) 1963–1971. DOI:<a href=\"https://doi.org/10.1056/NEJMoa1406766\">10.1056/NEJMoa1406766</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25264305/\">https://pubmed.ncbi.nlm.nih.gov/25264305</a></p></li><li><p>Johnson, TR, et al., &amp; Smith, BJ (2015). Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 45(1) 45–59. DOI:<a href=\"https://doi.org/10.3109/00498254.2014.941964\">10.3109/00498254.2014.941964</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25034009/\">https://pubmed.ncbi.nlm.nih.gov/25034009</a></p></li><li><p>Xu, H, et al., &amp; Bello, A (2015). Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. <i>Journal of clinical pharmacology</i> 55(1) 104–113. DOI:<a href=\"https://doi.org/10.1002/jcph.356\">10.1002/jcph.356</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24990113/\">https://pubmed.ncbi.nlm.nih.gov/24990113</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Crizotinib;
